The FDA designates AbbVie's (ABBV -0.8%) IL-23 inhibitor risankizumab (ABBV-066) an Orphan Drug for the treatment of pediatric patients with Crohn's disease. It is currently in Phase 2 development for adults with Crohn's. Other indication being investigated are asthma, plaque psoriasis and psoriatic arthritis.
Among the benefits of Orphan Drug status is an additional seven-year period of market exclusivity, if approved.
The company licensed risankizumab from Boehringer Ingelheim in March.